MaaT Pharma announces partnership with Clinigen

• MaaT Pharma and Clinigen signed exclusive long-term licensing and distribution agreement and commercial supply agreement for Xervyteg® (MaaT013), its first in class treatment proposed for patients with acute Graft-versus-Host Disease
  In June 2025, the European Medicines Agency accepted for review the marketing authorization submission for this medicine
• MaaT Pharma will receive a €10.5 million upfront payment, further potential regulatory and sales milestones of up to €18 million, and royalties of a mid-thirties’ percentage on net sales. MaaT Pharma also entered into a supply agreement to provide Clinigen with finished medicine, at a pre-agreed price per unit
• If this medicine is approved with potential marketing authorization granted by mid-2026, it has the potential to be the first microbiota therapeutic approved in Europe, the first one in hemato-oncology globally and the first and only one in third-line aGvHD 

Read the press release